Literature DB >> 16094417

Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.

P Niscola, M I Del Principe, L Maurillo, A Venditti, F Buccisano, D Piccioni, S Amadori, G Del Poeta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16094417     DOI： 10.1038/sj.leu.2403914

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

2.  Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients.

Authors:  Xiangsheng Xu; Qinghua Shang; Xinyue Chen; Weimin Nie; Zhengsheng Zou; Ang Huang; Ming Meng; Lei Jin; Ruonan Xu; Ji-Yuan Zhang; Junliang Fu; Lifeng Wang; Zirong Tang; Yunbo Xie; Xiaoming Yang; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2015-04-06       Impact factor: 11.530

Review 3.  Rituximab in chronic lymphocytic leukemia.

Authors:  Danelle F James; Thomas J Kipps
Journal:  Adv Ther       Date:  2011-07-02       Impact factor: 3.845

Review 4.  Infections associated with monoclonal antibody and fusion protein therapy in humans.

Authors:  Florence Uettwiller; Emilie Rigal; Cyrille Hoarau
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

5.  Patients with hematological malignancies and serological signs of prior resolved hepatitis B.

Authors:  Massimo Marignani; Elia Gigante; Paola Begini; Alfredo Marzano; Michela di Fonzo; Ilaria Deli; Sara Gallina; Maria Christina Cox; Gianfranco Delle Fave
Journal:  World J Gastrointest Oncol       Date:  2012-03-15

6.  Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?

Authors:  Jinoos Yazdany; Leonard Calabrese
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

7.  Detection of the Incidence of HBV, HCV Infection and Febrile Neutropenia Associated With CHOP With or Without Rituximab in Diffuse Large B-Cell Lymphoma-Treated Patients.

Authors:  Kashif Ali; Ali Akbar Sial; Mirza Tasawer Baig; Nida Baig; Saqib Hussain Ansari; Tahir Sultan Shamsi
Journal:  Hosp Pharm       Date:  2017-11-16

8.  Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.

Authors:  Yin-Hua Wang; Lei Fan; Li Wang; Run Zhang; Ji Xu; Cheng Fang; Jian-Yong Li; Wei Xu
Journal:  Support Care Cancer       Date:  2012-11-15       Impact factor: 3.603

Review 9.  Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis.

Authors:  Simone Lanini; Aoife C Molloy; Paul E Fine; Archibald G Prentice; Giuseppe Ippolito; Christopher C Kibbler
Journal:  BMC Med       Date:  2011-04-12       Impact factor: 8.775

10.  Role of rituximab in first-line treatment of chronic lymphocytic leukemia.

Authors:  Jeffrey Bryan; Gautam Borthakur
Journal:  Ther Clin Risk Manag       Date:  2010-12-22       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.